| Health / Medical Topics |
MART-1:26-35(27L) Peptide Vaccine
A peptide-based cancer vaccine consisting of amino acid residues 26 through 35 of MART-1 (melanoma antigen recognized by T-cells-1) with a leucine substitution at amino acid position 27 to improve immunogenicity. Upon administration, MART-1:26-35(27L) peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against MART-1-expressing tumor cells, resulting in decreased tumor growth. The tumor-associated antigen (TAA) MART-1 may be overexpressed on melanoma cancer cells. (NCI Thesaurus)
YOU MAY ALSO LIKE
A cancer vaccine consisting of an attenuated recombinant vaccinia virus expressing the melanoma-associated antigen MART-1. Vaccination with this agent may stimulate cytotoxic…
Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A)…
A synthetic cancer vaccine derived from a melanoma-associated antigen, MART-1. Antigenic peptides derived from MART-1 are recognized by CD8+ T lymphocytes…
A protein found on normal melanocytes (cells that make the pigment melanin) in the skin and in the retina. It is also…
A vaccine consisting of recombinant adenovirus vector encoding MART-1 (melanoma antigen recognized by T-cells 1), an immunogenic protein of unknown function that…
A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory…
